# AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer

> **NCT07146919** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Centre Leon Berard**

## Conditions studied

- Endometrial Carcinoma
- Ovarian Cancer
- Cervix Cancer

## Interventions

- **DRUG:** Bemarituzumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07146919
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-10-15
- **Primary completion:** 2030-10-15
- **Final completion:** 2030-10-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Molecule not available from the laboratory
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07146919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07146919, "AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07146919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*